Review: Selective serotonin reuptake inhibitors are more tolerable than tricyclic antidepressant drugs


**Question**
On the basis of patient discontinuation rates, are selective serotonin reuptake inhibitors (SSRIs) more tolerable than tricyclic and heterocyclic antidepressant drugs?

**Data sources**
Studies were identified by searching MEDLINE (1966 to 1999) and EMBASE (1974 to 1999) with drug names; conference abstracts; government documents; and the 1997 to 1999 Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register. Specialist journals and reference lists of relevant studies and systematic reviews were hand searched.

**Study selection**
Randomized, blinded, controlled trials involving patients (age ≥ 18 y) diagnosed with depression were selected if they compared an SSRI (fluoxetine, fluvoxamine, sertraline, paroxetine, or citalopram) with old tricyclics (amitriptyline or imipramine), newer tricyclics (clomipramine, desipramine, dothiepin, doxepin, lofepramine, or nortriptyline), or heterocyclic and related drugs (aminptine, bupropion, maprotiline, mianserin, or trazodone) and if data on dropouts (patients not completing study after allocation) were available.

**Main results**
136 randomized controlled trials met the criteria. 84% of the studies had a follow-up of ≤ 6 weeks (4 wk to 1 y), 58% were in outpatient settings, and < 25% were done completely in inpatient settings. Patients receiving SSRIs had a lower total dropout rate than did those receiving old and newer tricyclics and did not differ from those receiving heterocyclics (Table). SSRIs had a higher dropout rate from inefficacy than did all other antidepressant drugs combined. SSRIs had a weighted dropout rate from side effects of 12% vs 18% for old tricyclics (odds ratio [OR] 0.62, 95% CI 0.54 to 0.71) and 10% vs 13% for newer tricyclics (OR 0.78, CI 0.63 to 0.98).

**Conclusion**
On the basis of patient discontinuation rates, selective serotonin reuptake inhibitors are somewhat more tolerable than the old and newer tricyclic antidepressant drugs.

**Source of funding:** No external funding.

For correspondence: Dr. M. Hotopf, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, England, UK. FAX 44-207-277-0283.

---

**Commentary**
Despite higher costs, SSRIs might be more cost-effective if they were better tolerated. This potential advantage has been calculated assuming the risk for dropout to be 8% to 12% lower for SSRIs. The systematic review by Barbui and colleagues found a 3% difference in overall adherence, which is not clinically significant: The number of patients needing treatment to prevent 1 additional dropout is 26. However, generalizing from randomized controlled trials to routine practice may not be justifiable.

First, most trials in the review continued for only 6 weeks, but in practice, medication is offered for approximately 6 months. Second, most trials in the review included only patients with no comorbid conditions, whereas in practice we need to consider drug interactions and side effects, such as the effect of tricyclics on heart disease.

Further evidence from real world practice is surprisingly scant. An observational study of the ratio of SSRI treatment discontinuations to inceptions in U.K. general practice found an 11% difference in favor of the SSRIs, and the practitioners in the study reported that in their view, lack of tolerability rather than inefficacy explained most of this difference (1). SSRIs also have the advantage of being prescribed at a dose that is therapeutic from the beginning; tricyclics often have to be titrated upward.

Although advantages may be overrated, in primary care practice, SSRIs have become the drug of first choice for most patients with depression, particularly because the drugs have started to come off patent with resultant lower costs.

**Reference**